JP2001011094A - 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 - Google Patents
乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法Info
- Publication number
- JP2001011094A JP2001011094A JP11224416A JP22441699A JP2001011094A JP 2001011094 A JP2001011094 A JP 2001011094A JP 11224416 A JP11224416 A JP 11224416A JP 22441699 A JP22441699 A JP 22441699A JP 2001011094 A JP2001011094 A JP 2001011094A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- active substance
- physiologically active
- whey protein
- milk whey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 167
- 210000004080 milk Anatomy 0.000 title claims abstract description 167
- 239000008267 milk Substances 0.000 title claims abstract description 166
- 239000013543 active substance Substances 0.000 title claims abstract description 132
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 91
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 91
- 235000021119 whey protein Nutrition 0.000 title claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 title claims description 44
- 210000002437 synoviocyte Anatomy 0.000 claims abstract description 42
- 241001465754 Metazoa Species 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 24
- 230000004663 cell proliferation Effects 0.000 claims abstract description 23
- 241000700605 Viruses Species 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract description 18
- 230000003053 immunization Effects 0.000 claims abstract description 12
- 235000020247 cow milk Nutrition 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 5
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 235000021277 colostrum Nutrition 0.000 claims description 45
- 210000003022 colostrum Anatomy 0.000 claims description 45
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 39
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 235000013365 dairy product Nutrition 0.000 claims description 19
- 230000000975 bioactive effect Effects 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 230000010261 cell growth Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 241000282326 Felis catus Species 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000005862 Whey Substances 0.000 claims description 6
- 229940088623 biologically active substance Drugs 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 235000020251 goat milk Nutrition 0.000 claims description 6
- 235000020252 horse milk Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 235000020254 sheep milk Nutrition 0.000 claims description 6
- 229960001438 immunostimulant agent Drugs 0.000 claims description 5
- 239000003022 immunostimulating agent Substances 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 230000035622 drinking Effects 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000003435 antirheumatic agent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 235000020186 condensed milk Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 235000015140 cultured milk Nutrition 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 235000015243 ice cream Nutrition 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000020124 milk-based beverage Nutrition 0.000 claims 1
- 235000011962 puddings Nutrition 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 239000000606 toothpaste Substances 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 6
- 206010003402 Arthropod sting Diseases 0.000 abstract 3
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 22
- 241000283690 Bos taurus Species 0.000 description 17
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 241000701931 Canine parvovirus Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 210000000991 chicken egg Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 3
- 241000589902 Leptospira Species 0.000 description 3
- 108700021154 Metallothionein 3 Proteins 0.000 description 3
- 102100028708 Metallothionein-3 Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101000886871 Liolophura japonica Globin-1 Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- UNQNIRQQBJCMQR-UHFFFAOYSA-N phosphorine Chemical compound C1=CC=PC=C1 UNQNIRQQBJCMQR-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 102200004779 rs2232775 Human genes 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241001046548 Anaerobium Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 206010006049 Bovine Tuberculosis Diseases 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001461464 Cymbocarpa refracta Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100533652 Homo sapiens SLIRP gene Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Dairy Products (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11224416A JP2001011094A (ja) | 1999-07-01 | 1999-07-01 | 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11224416A JP2001011094A (ja) | 1999-07-01 | 1999-07-01 | 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001011094A true JP2001011094A (ja) | 2001-01-16 |
| JP2001011094A5 JP2001011094A5 (enExample) | 2006-09-07 |
Family
ID=16813443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11224416A Pending JP2001011094A (ja) | 1999-07-01 | 1999-07-01 | 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001011094A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113855787A (zh) * | 2020-06-30 | 2021-12-31 | 北京大学 | 乳清蛋白作为冠状病毒广谱抑制剂的用途 |
-
1999
- 1999-07-01 JP JP11224416A patent/JP2001011094A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113855787A (zh) * | 2020-06-30 | 2021-12-31 | 北京大学 | 乳清蛋白作为冠状病毒广谱抑制剂的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2260007C (en) | Method for treating gastrointestinal damage | |
| RU2217152C2 (ru) | Колостринин и его применение | |
| EP0704218B1 (en) | Bone reinforcing agent and foods and drinks product containing the same | |
| ES2249207T3 (es) | Agente de supresion de la resorcion osea. | |
| JP3929088B2 (ja) | 骨形成促進及び骨吸収防止剤 | |
| JP2002501526A (ja) | 乳汁における免疫グロブリンａの生成方法 | |
| CA2013941A1 (en) | Process for preparing a therapeutic agent for rotavirus infection | |
| JP2001515050A (ja) | 動物における筋肉タンパク質の増加および脂肪の減少方法 | |
| US20020044942A1 (en) | Transfer factor composition and process for producing same | |
| US8252341B2 (en) | Isolation of growth and differentiating factors from colostrum | |
| EA016039B1 (ru) | Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления | |
| Sydney et al. | Colostrum new insights: products and processes | |
| JP3604159B2 (ja) | 乳清由来の骨芽細胞増殖促進及び骨強化因子ならびに該因子を含有せしめた骨強化食品、医薬および飼料 | |
| JP2001011094A (ja) | 乳ホエ−タンパク中の生理活性物質およびその製造法ならびにその使用法 | |
| US7083809B2 (en) | Purified cytokine inhibitory factor | |
| RU2062109C1 (ru) | Способ получения иммунного препарата | |
| JP4911894B2 (ja) | 関節リウマチを予防するための経口投与用組成物 | |
| RU2073509C1 (ru) | Препарат для лечения желудочно-кишечных заболеваний телят и способ лечения желудочно-кишечных заболеваний телят | |
| JP2025090310A (ja) | 骨形成促進用組成物 | |
| CN107106661A (zh) | 用于增加动物中的血清igf‑1的方法 | |
| TWI620508B (zh) | 飲料及其製造方法 | |
| JPH0930986A (ja) | 牛科動物の免疫方法 | |
| JP2008179572A (ja) | 免疫グロブリンＦｃフラグメントレセプタータンパク及び／又は免疫グロブリンＦｃフラグメントレセプター様タンパク産生抑制剤及びその使用 | |
| AU9514701A (en) | Colostrinin, and uses thereof | |
| MXPA99000772A (en) | Method for treating gastrointestinal damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060627 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060627 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060627 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080304 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080701 |